Suppr超能文献

MitraClip系统:适应症、操作要求及指南的系统评价

The MitraClip System: a systematic review of indications, procedural requirements, and guidelines.

作者信息

Bail Dorothee Hl, Doebler Klaus

机构信息

Competence-Center Quality Assurance, Medical Service of Statutory, Healthcare Insurance, Tuebingen and Stuttgart, Germany.

出版信息

Thorac Cardiovasc Surg. 2014 Feb;62(1):18-25. doi: 10.1055/s-0033-1360509. Epub 2013 Dec 2.

Abstract

BACKGROUND

Transcatheter interventions (TIs) are new treatment options for patients with severe mitral valve regurgitation (MR) who cannot undergo open mitral valve surgery (oMVS). Despite the lack of scientific evidence demonstrating the benefit of these procedures, there has been a steady increase in their use. The aim of this study was to evaluate whether there are any indication criteria, process, and structural requirements, or scientific society and institutional guidelines for the use of the MitraClip System (Abbott Vascular-Structural Heart, Menlo Park, California, United States).

METHOD

A systematic literature search was conducted using the common medical and scientific databases. Of a total of 1,395 publications, 42 publications met the inclusion criteria and were included for the evaluation.

RESULTS

Despite a general lack of high-quality evidence and of consensus recommendations from scientific societies or institutions, an assessment of indication criteria and process and structural requirements for the use of the MitraClip System, including noncontrolled studies, was possible. The majority of studies agree that an interdisciplinary heart team including a cardiothoracic surgeon, an interventional cardiologist, and an echocardiographic specialist should actively participate in clinical decision making, and in the procedure itself. Participation in a scientific-based registry is strongly recommended.

CONCLUSIONS

The MitraClip System is a promising procedure, but evidence-based indication criteria, structural, and process requirements for its use are lacking. Further results from prospective, randomized controlled trials are needed to determine patients, potential adverse events, device durability, and long-term follow-up. MitraClip should be used in only a small number of centers with procedure-specific, high-quality surgical and interventional experience, and training.

摘要

背景

经导管介入治疗(TIs)是无法接受二尖瓣开放手术(oMVS)的重度二尖瓣反流(MR)患者的新治疗选择。尽管缺乏科学证据证明这些手术的益处,但它们的使用却在稳步增加。本研究的目的是评估使用MitraClip系统(美国加利福尼亚州门洛帕克市雅培血管结构心脏公司)是否存在任何适应症标准、流程和结构要求,或科学协会及机构指南。

方法

使用常见的医学和科学数据库进行系统的文献检索。在总共1395篇出版物中,42篇符合纳入标准并被纳入评估。

结果

尽管普遍缺乏高质量证据以及科学协会或机构的共识性建议,但对使用MitraClip系统的适应症标准、流程和结构要求进行评估(包括非对照研究)是可行的。大多数研究一致认为,包括心胸外科医生、介入心脏病专家和超声心动图专家在内的跨学科心脏团队应积极参与临床决策及手术本身。强烈建议参与基于科学的注册研究。

结论

MitraClip系统是一种有前景的手术方法,但缺乏基于证据的使用适应症标准、结构和流程要求。需要前瞻性随机对照试验的进一步结果来确定患者、潜在不良事件、器械耐久性和长期随访情况。MitraClip仅应在少数具备特定手术、高质量外科和介入经验及培训的中心使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验